Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
CERE was delisted on the 31st of July, 2024.
195 hedge funds and large institutions have $6.64B invested in Cerevel Therapeutics Holdings, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 91 funds opening new positions, 61 increasing their positions, 33 reducing their positions, and 15 closing their positions.
507% more first-time investments, than exits
New positions opened: 91 | Existing positions closed: 15
175% more funds holding in top 10
Funds holding in top 10: 4 → 11 (+7)
116% more capital invested
Capital invested by funds: $3.07B → $6.64B (+$3.57B)
85% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 33
64% more funds holding
Funds holding: 119 → 195 (+76)
3% more call options, than puts
Call options by funds: $79.6M | Put options by funds: $77.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$190M |
| 2 |
BCI
Bain Capital Investors
Boston,
Massachusetts
|
+$157M |
| 3 |
Fidelity International
Hamilton,
Bermuda
|
+$79.5M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$54.9M |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$49.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$400M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$137M |
| 3 |
AG
Artal Group
Luxembourg
|
-$46.9M |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$39.8M |
| 5 |
Millennium Management
New York
|
-$29.3M |
CERE Hedge Fund Activity: Q4 2023 in Review
195 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) for Q4 2023, worth a combined $6.64B — up 116% from $3.07B a quarter earlier.
Buyers outnumbered sellers: 91 funds opened new CERE positions and 15 closed out — a net gain of 76 holders — while 61 added to existing stakes and 33 trimmed.
The largest buyer was Avoro Capital Advisors, adding an estimated $190M. The largest seller was Fidelity Investments, cutting an estimated $400M.
- 195 institutional investors held Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) as of Q4 2023, up from 119 in Q3 2023.
- Funds reported $6.64B of Cerevel Therapeutics Holdings, Inc. Common Stock stock for Q4 2023, up 116% quarter-over-quarter.
- 91 funds opened new Cerevel Therapeutics Holdings, Inc. Common Stock positions in Q4 2023 and 15 closed out, a net change of +76 holders.
- The largest Cerevel Therapeutics Holdings, Inc. Common Stock buyer in Q4 2023 was Avoro Capital Advisors, an estimated $190M added.
- The largest Cerevel Therapeutics Holdings, Inc. Common Stock seller in Q4 2023 was Fidelity Investments, an estimated $400M sold.
Based on aggregated 13F filings for Q4 2023.